The progresses of relevant factors on the efficacy of immune checkpoint inhibitors in the non-small cell lung cancer patients

Abstract

Lung cancer has the highest mortality rate of all cancers worldwide. Although immune checkpoint inhibitor (ICI)-based therapy can improve the survival of patients with lung cancer, its efficacy is affected by many factors. Therefore, it is necessary to identify factors that affect the efficacy of ICI-based treatment and establish a model for predicting drug response and resistance before and during treatment for individualized and accurate treatment of patients. This review summarizes the clinical and biological factors related to ICI-based treatment of non-small cell lung cancer (NSCLC) and the recent research progress of predictive models for assessing ICI efficacy.

Keywords

• Non-small cell lung cancer
• Immune checkpoint inhibitor (ICI)
• Predictive biomarkers
• Predictive model